BSE: 543616 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Trident Lifeline Ltd is a average quality company.
The key valuation ratios of Trident Lifeline Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Trident Lifeline Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|
| ROCE % ⓘ | -9.1% | 33.7% | 55.1% | 25.1% | 19.1% | - |
| Value Creation Index ⓘ | NA | 1.4 | 2.9 | 0.8 | 0.4 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | ||||||
| Sales ⓘ | 4.9 | 9.6 | 21.8 | 31.7 | 44.7 | 45 |
| Sales YoY Gr. | - | 95.1% | 126.3% | 45.6% | 40.9% | - |
| Adj EPS ⓘ | -2.6 | 1.2 | 4.9 | 5.1 | 6 | 6.1 |
| YoY Gr. | - | NA | 314.5% | 5.2% | 18% | - |
| BVPS (₹) ⓘ | -9.7 | -0.9 | 6 | 39.7 | 45.8 | 51.4 |
| Adj Net Profit ⓘ | -0.8 | 0.6 | 3.9 | 5.9 | 6.9 | 7 |
| Cash Flow from Ops. ⓘ | -0.6 | 1.5 | -0.2 | -16.6 | 0.9 | - |
| Debt/CF from Ops. ⓘ | -10.9 | 3.1 | -12.8 | -0.2 | 6.9 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 66.8% | 40.9% | ||||
| Adj EPS ⓘ | NA | NA | 72.6% | 18% | ||||
| BVPSⓘ | NA | NA | NA | 15.5% | ||||
| Share Price | - | - | - | 56.2% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 27.1 | -33.6 | 180.3 | 23.3 | 14.1 | 12.6 |
| Op. Profit Mgn % ⓘ | -5.5 | 13 | 12.4 | 19.8 | 19.9 | 25.4 |
| Net Profit Mgn % ⓘ | -16.5 | 6.1 | 17.8 | 18.5 | 15.5 | 15.8 |
| Debt to Equity ⓘ | -2.2 | -9.6 | 0.5 | 0.1 | 0.1 | 0.1 |
| Working Cap Days ⓘ | 0 | 223 | 164 | 267 | 355 | 89 |
| Cash Conv. Cycle ⓘ | 0 | 30 | 33 | 95 | 118 | 60 |
Sales growth is growing at healthy rate in last 3 years 66.81%
Net Profit is growing at healthy rate in last 3 years 72.64%
Sales growth is good in last 4 quarters at 43.26%
Return on Equity has declined versus last 3 years average to 12.60%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 6.1 | 5.5 |
| TTM Sales (₹ Cr.) | 44.7 | 44.6 |
| BVPS (₹.) ⓘ | 51.4 | 48.3 |
| Reserves (₹ Cr.) ⓘ | 48 | 46 |
| P/BV ⓘ | 5.35 | 5.69 |
| PE ⓘ | 44.90 | 49.85 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 136.00 / 339.00 |
| All Time Low / High (₹) | 102.75 / 339.00 |
| Market Cap (₹ Cr.) | 316 |
| Equity (₹ Cr.) | 11.5 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.76 | 0.00 | 0.00 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|
| Sales | 5 | 10 | 22 | 32 | 45 |
| Operating Expenses ⓘ | 5 | 8 | 19 | 25 | 36 |
| Manufacturing Costs | 0 | 1 | 5 | 5 | 6 |
| Material Costs | 3 | 6 | 11 | 16 | 25 |
| Employee Cost | 1 | 1 | 1 | 1 | 2 |
| Other Costs ⓘ | 1 | 1 | 3 | 3 | 3 |
| Operating Profit ⓘ | 0 | 1 | 3 | 6 | 9 |
| Operating Profit Margin (%) | -5.5% | 13.0% | 12.4% | 19.8% | 19.9% |
| Other Income ⓘ | 0 | 0 | 1 | 1 | 2 |
| Interest ⓘ | 1 | 0 | 0 | 0 | 1 |
| Depreciation ⓘ | 0 | 0 | 0 | 0 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -1 | 1 | 3 | 7 | 10 |
| Tax ⓘ | 0 | 0 | -1 | 1 | 3 |
| Profit After Tax | -1 | 1 | 4 | 6 | 7 |
| PAT Margin (%) | -16.1% | 6.6% | 18.1% | 19.0% | 15.8% |
| Adjusted EPS (₹) | -2.6 | 1.3 | 4.9 | 5.2 | 6.1 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | -3 | 0 | 5 | 46 | 53 | |||||
| Share Capital ⓘ | 3 | 5 | 8 | 11 | 11 | |||||
| Reserves ⓘ | -6 | -5 | -3 | 34 | 41 | |||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |||||
| Debt | 6 | 5 | 2 | 3 | 6 | |||||
| Long Term Debt | 6 | 5 | 1 | 0 | 4 | |||||
| Short Term Debt | 0 | 0 | 1 | 3 | 2 | |||||
| Trade Payables | 2 | 4 | 5 | 5 | 8 | |||||
| Others Liabilities ⓘ | -1 | 2 | 1 | 3 | 8 | |||||
| Total Liabilities ⓘ | 4 | 10 | 13 | 56 | 74 | |||||
Fixed Assets | ||||||||||
| Gross Block | 1 | 2 | 2 | 4 | 10 | |||||
| Accumulated Depreciation | 0 | 1 | 1 | 1 | 2 | |||||
| Net Fixed Assetsⓘ | 1 | 1 | 1 | 3 | 8 | |||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | 4 | |||||
| Investmentsⓘ | 0 | 0 | 0 | 4 | 4 | |||||
| Inventories | 1 | 5 | 4 | 7 | 11 | |||||
| Trade Receivables | 1 | 1 | 5 | 12 | 14 | |||||
| Cash Equivalents | 0 | 0 | 0 | 14 | 6 | |||||
| Others Assetsⓘ | 1 | 2 | 3 | 16 | 27 | |||||
| Total Assets ⓘ | 4 | 10 | 13 | 56 | 74 | |||||
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -1 | 1 | 0 | -17 | 1 |
| PBT ⓘ | -1 | 1 | 3 | 7 | 10 |
| Adjustment ⓘ | 1 | 1 | 0 | 0 | -1 |
| Changes in Working Capital ⓘ | -0 | 0 | -4 | -23 | -6 |
| Tax Paid ⓘ | 0 | 0 | 0 | -1 | -2 |
| Cash Flow From Investing Activity ⓘ | 0 | -1 | 0 | -6 | -11 |
| Capex | 0 | -1 | 0 | -2 | -9 |
| Net Investments | 0 | 0 | 0 | -4 | 0 |
| Others ⓘ | 0 | 0 | 0 | 1 | -2 |
| Cash Flow From Financing Activityⓘ | 1 | -1 | 1 | 36 | 2 |
| Net Proceeds from Shares ⓘ | 1 | 2 | 3 | 35 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | -2 | -3 | -1 | 3 |
| Interest Paid ⓘ | -1 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | -1 | 1 | 2 | 0 |
| Net Cash Flow ⓘ | 0 | 0 | 0 | 14 | -8 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | N/A | N/A | 183.4 | 23.87 | 14.34 | |||||
| ROCE (%) | N/A | N/A | 55.11 | 25.1 | 19.11 | |||||
| Asset Turnover Ratio | 1.14 | 1.38 | 1.94 | 0.92 | 0.69 | |||||
| PAT to CFO Conversion(x) | N/A | 1 | 0 | -2.83 | 0.14 | Working Capital Days | ||||
| Receivable Days | 97 | 37 | 47 | 99 | 106 | |||||
| Inventory Days | 69 | 118 | 75 | 63 | 75 | |||||
| Payable Days | 202 | 194 | 157 | 112 | 90 | |||||
The Company was originally incorporated as “Trident Lifeline Private Limited” as a Private Limited Company under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated January 09, 2014, issued by the Registrar of Companies, Gujarat, Dadra and Nagar Havelli. Subsequently, the Company was converted into a Public Limited Company pursuant to shareholders resolution passed at Extra-ordinary General Meeting of the Company held on June 02, 2022 and the name of the Company was changed to “Trident Lifeline Limited”. A fresh Certificate of Incorporation consequent upon Conversion from Private Limited Company to Public Limited Company dated June 10, 2022 was issued by the Registrar of Companies, Ahmedabad.
Trident Lifeline is engaged in the pharmaceutical business ethical marketing in domestic as well as international market. It is also engaged in distribution of pharmaceutical products through third party distribution network. It offers wide range of pharmaceutical formulations and products manufactured on contract manufacturing under loan lisence. It operates in India as well as African, Latin American and East Indian Countries. It has its presence through registered products or products under registration in countries like Bolivia, Cambodia, Cameroon, Chile, Ghana, Kenya, Myanamar, Nigeria, Peru, Sudan, Tajikistan, Uzbekistan, Venuzela.
The company is engaged in the business of marketing pharmaceutical products. For which it has obtain necessary approvals from FDA for getting the formulations manufacture from contract manufacturers on Loan License or on principle-to-principle basis. It also takes the necessary Trademark approvals & registrations wherever required. Its Pharma business operations are supported by various contract manufacturers having facilities which are approved by FDA/WHO and other relevant authorities. It typically works on contract manufacturing basis or at times purchase order basis, depending upon customer’s requirement, with manufacturer of pharma products. Presently the company operates with one contract manufacturer. The company has maintained relationship with the regular supplier, having FDA and WHO approved plant to supply pharma formulations. These units manufacture tablets, capsules, dry powder, syrup under its own brands.
Business area of the company
The company is engaged in the manufacturing and marketing of quality finished dosages. It is one of the fastest growing pharmaceutical companies in the SME segment providing unprecedented quality of healthcare products. It deals in Capsules, Tablets, Liquid Ointment, Gel, Ice Gel, Mouthwash, Paste, Solution, Suspension, Drypowders and Toothpaste. Its product portfolio comprises of vide range of drugs like Anti Bacterial, Anti Diarrheal, Anti Fungal, Anti Malerial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozol, Anti Histamine, Anti Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral Nyteraceutical and Non-steriodal anti-inflamatory drug (NSAIDS).
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
